SWM
ELTX icon

Spire Wealth Management’s Elicio Therapeutics ELTX Stock Holding History

Spire Wealth Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-350
Closed -$64K – 2683
2021
Q1 		$64K Buy
+350
New +$67.6K ﹤0.01% 1600

Other funds holding ELTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Spire Wealth Management's ELTX Position: Q2 2021 in Review

Spire Wealth Management sold out of Elicio Therapeutics (ELTX) in Q2 2021, closing a stake of 350 shares — an estimated $64K sold.

Spire Wealth Management first reported a position in ELTX in Q1 2021 and held it in 1 quarter. The position peaked at $64K in Q1 2021. 41 funds tracked by Wall St. Rank hold ELTX as of Q2 2021.

  • Spire Wealth Management reported no remaining Elicio Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Spire Wealth Management sold 350 Elicio Therapeutics shares in Q2 2021, an estimated $64K.
  • Spire Wealth Management first reported a position in Elicio Therapeutics in Q1 2021 and held it in 1 quarter.
  • Spire Wealth Management's Elicio Therapeutics position peaked at $64K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2021.

Based on Spire Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.